Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced that the company’s president and CEO Nader Pourhassan was interviewed on Uptick Newswire’s “Stock Day” Podcast. Among other highlights, Pourhassan discussed the company’s main product, a humanized monoclonal antibody, which has demonstrated positive results in HIV patients in a human clinical trial. The antibody has received fast-track designation with the FDA, with the potential of approval in early 2019. In addition, Pourhassan discussed a letter of intent and acquisition of a company with advanced cancer treatment and the company’s newly-hired board member, Michael Klump.
To listen to the full interview, visit http://nnw.fm/u2rHK
To view the full press release, visit http://nnw.fm/m6iND
CytoDyn, Inc. is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn’s lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments. The clinical-stage biotechnology company engages in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. Its product pipeline includes PRO 140, CytoFeline, and Cytolin. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA. For more information, visit the company’s website at www.Cytodyn.com.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
New York, New York